Rachel Salzman | CEO
Armatus Bio

Dr. Rachel Salzman is Chief Executive Officer at Armatus Bio, a privately held preclinical stage biotech focusing on precision therapies for genetic neuromuscular disorders. For over 20 years, Dr. Salzman has provided drug development expertise in the rare disease space where complex biological and business issues intersect with serious unmet medical need. Prior to joining Armatus, Rachel was Executive Vice President of Portfolio, External Affairs & Development at Alcyone Therapeutics. She co-founded SwanBio Therapeutics in 2017, subsequently acquired by Spur Therapeutics, and served as CEO through 2019. She then founded UltraSquared Bio, a not-for-profit organization dedicated to bringing gene therapies to ultra-rare populations where traditional business cases are not tractable, and in this capacity was awarded a prestigious Termeer Foundation Fellowship. Prior to her time at Swan, she was the Chief Science Officer (CSO) of The Stop ALD Foundation. Dr. Salzman’s impact is a result of her unique leadership ability and successful aggregation of resources and commitment from investigators, technologists, and investors. Dr. Salzman has been an active member of ASGCT for over 20 years and has served on multiple committees and task forces, in addition to the Board of Directors. She currently represents ASGCT at the National Academy of Sciences' Forum on Regenerative Medicine. Dr. Salzman received her DVM from Oklahoma State University and a bachelor’s degree in animal science from Rutgers University.